TokyoTokyo Mon - Fri 10:00-18:00 +81 (368) 662-975
info@mountequitygroup.com

India’s Piramal Enterprises to demerge and list pharma business

Mount Equity Group Tokyo, Japan > News > Business > India’s Piramal Enterprises to demerge and list pharma business

An employee carries test tubes inside a laboratory at Piramal’s Research Centre in Mumbai August 11, 2014. REUTERS/Danish Siddiqui

BENGALURU, Oct 7 (Reuters) – Indian conglomerate Piramal Enterprises Ltd (PEL) (PIRA.NS) said on Thursday it was demerging its pharmaceutical business and listing it as a separate entity as part of a move to simplify its corporate structure.

Piramal’s pharma business will now be demerged and consolidated under its unit Piramal Pharma. Shareholders of Piramal will get four shares of Piramal Pharma for every share they hold in the conglomerate.

Piramal will also merge its shadow lending unit PHL Fininvest with itself to create a large non-banking financial company, with a focus on retail and wholesale financing and a consolidated loan book of 650 billion rupees ($8.69 billion), the company said in an exchange filing.

The moves will enable the entities to independently pursue their growth strategies with…

Read more…